Business highlights in Q4 2022
- On October 4th the Company announced the outcome of the incentive program ‘LTI2022’ approved by the AGM on May 24th 2022.
- On November 4th the Company provided an update on its clinical programs.
- On December 20th the Company started a Phase 1 pharmacokinetics study for new IP2015 formulations.
- On December 23rd the Company announced that it had decided not to exercise the option for an undisclosed pain asset.
Business highlights after this reporting period
- Nothing to report.
Financial Highlights
Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK).
| Fourth Quarter (2022-10-01 – 2022-12-31) |
| Net revenue were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -6,477 (-7,280) |
| Earnings per share was DKK –0.06 (-0.11) |
| Cash: TDKK 39,112 (34,346) |
| Solidity: 72% (92%) |
| Full Year (2022-01-01 – 2022-12-31) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -41,740 (-23,072) |
| Earnings per share was DKK –0.73 (-0.60) |
As disclosed in the Q1:2022 report Initiator Pharma publishes its interim reports in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/